Chronic Spontaneous Urticaria (CSU) - Epidemiology Forecast - 2034
Description
Key Highlights
DelveInsight’s analyst projects that in 2024, the 7MM reported approximately 4.7 million prevalent cases of chronic urticaria, reflecting a significant disease burden. Of these, approximately 69% were classified as Chronic Spontaneous Urticaria (CSU) and around 31% as chronic inducible urticaria (CIndU), with CSU accounting for the larger proportion.
In 2024, DelveInsight’s analyst estimates that the total number of diagnosed prevalent cases of CSU across the 7MM was approximately 3.2 million. Among these, the US accounted for around 18.5%, EU4 and the UK collectively contributed 44.3%, while Japan accounted for the remaining 37.2%. The diagnosed prevalent cases of CSU across the 7MM are projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 3% over the forecast period (2025–2034).
According to DelveInsight analysis, in 2024, females accounted for approximately 73% of CSU cases in the US, while males represented around 27%. The higher prevalence in females is expected to continue through 2034, primarily due to hormonal and immunological differences that increase susceptibility to autoimmune and allergic conditions such as CSU.
According to DelveInsight’s 2024 estimates, the severity-specific prevalence of CSU in the EU4 and the UK was distributed as approximately 18% mild, 37% moderate, and 45% severe cases. These proportions are expected to increase by 2034 due to evolving diagnostic practices and healthcare technologies.
DelveInsight’s epidemiological model estimates that in 2024, the 18–29 age group in Japan had the highest CSU cases, nearly 300 thousand cases. In contrast, the 60 years and above age group had the fewest cases, with around 60 thousand cases.
CSU is frequently diagnosed through exclusion, which contributes to delayed specialist referrals, excessive diagnostic procedures, and increased patient dissatisfaction—largely driven by limited awareness and recognition of the condition among primary care providers.
DelveInsight’s “Chronic Spontaneous Urticaria (CSU) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of CSU, historical and forecasted epidemiology of CSU in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Chronic Spontaneous Urticaria Understanding
CSU Overview
Urticaria is a common and heterogeneous inflammatory skin disorder with or without associated angioedema. It presents with wheals, angioedema, or both due to activation and degranulation of skin mast cells, followed by the release of histamine and other mediators leading to sensory nerve activation, vasodilatation, plasma extravasation, and cellular recruitment. It is classified as acute or chronic, depending on whether the onset of episodes lasts for less or >6 weeks, respectively.
Chronic urticaria is spontaneous or inducible, lasts >6 weeks, and persists for >1 year. It impacts the quality of life and is linked to psychiatric comorbidities and high healthcare costs, often causing huge socio-economic distress for the patients. In contrast to CSU, where the cause is unknown, chronic inducible urticaria has definite and subtype-specific triggers that induce signs and symptoms.
A mast cell-driven disease is characterized by recurrent itchy wheals (hives) that may accompany angioedema, due to activation and degranulation of skin mast cells, followed by the release of histamine and other mediators. The typical lesion is a pale-to-red, well-demarcated papule or plaque. Lesions may be round, oval, annular, arcuate, serpiginous, or generalized. They resolve without post-inflammatory pigmentary changes or scaling. Women are twice as likely as men to be diagnosed with the disease, and most people first develop symptoms between 20 and 40 years.
The etiology of CSU is yet to be fully established. The exact cause is often unknown, but it may be due to autoimmune reactions wherein the immune system mistakenly targets healthy cells in the skin. Other potential triggers include medications, infections, insect bites, stress, and temperature changes. The prognosis in CSU depends on the comorbid disease causing the urticaria and the patient’s response to therapy. The autoimmune pathogenesis of chronic urticaria, including recent data, suggests that CSU may involve contributions from both immunoglobulin G (IgG)-specific and immunoglobulin E (IgE)-specific autoantibodies against a vast array of antigens that can span beyond those found on the surface of mast cells and basophils.
CSU Diagnosis
The diagnosis is based on a physical examination and medical history. Additional tests are performed to rule out underlying causes or to identify triggers, such as blood tests, allergy tests, or skin biopsies. Screening tests for thyroid function and antithyroid peroxidase and antithyroglobulin antibodies are recommended. Positive autologous serum skin test (ASST) and in vitro testing of the patient’s serum for the anti-FCeRIa or the anti-IgE autoantibodies by basophil histamine release assay (BHRA) is also recommended.
Some tools have been developed to assess disease activity (e.g., urticaria activity score), disease control (e.g., urticaria control test), and impacts on quality of life (e.g., chronic urticaria quality of life index).
Further details related to diagnosis are provided in the report…
Chronic Spontaneous Urticaria Epidemiology
For the purpose of designing the patient-based model for CSU, the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of chronic urticaria, type-specific cases of chronic urticaria, gender-specific cases of CSU, age-specific cases of CSU, and severity-specific cases of CSU in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.
According to DelveInsight’s estimates, the total diagnosed prevalent cases of chronic urticaria in the 7MM were approximately 4.5 million in 2024, with these numbers anticipated to increase by 2034.
Among the 7MM, the US accounted for nearly 19% of the total diagnosed prevalent cases of chronic urticaria, with around 885 thousand cases in 2024. These cases are expected to change during the forecast period (2025–2034). The EU4 and the UK accounted for approximately 39% of the total cases, while Japan accounted for around 42% in 2024.
DelveInsight’s estimates indicate that type-specific diagnosed prevalent cases of chronic urticaria, including CSU and Chronic Inducible Urticaria (CIndU), were nearly 3.2 million and 1.5 million cases, respectively, in 2024 in the 7MM.
The US accounted for approximately 600 thousand diagnosed prevalent cases of CSU in 2024, and these cases are projected to increase by 2034.
In 2024, among the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases of CSU with approximately 375 thousand cases, while Spain reported the lowest.
Japan accounted for nearly 37% of the total diagnosed prevalent CSU cases across the 7MM in 2024.
As per the estimates, CSU shows a significant female predominance compared to males. In 2024, the US reported approximately 150 thousand diagnosed prevalent cases of CSU in males and around 430 thousand cases in females, underscoring a significantly higher burden among the female population.
According to DelveInsight’s age-specific prevalence estimates, in the EU4 and the UK, the age group =60 years represented the highest number of diagnosed CSU cases in 2024, with nearly 445 thousand cases, followed by the 50–59 years age group, with around 235 thousand cases.
DelveInsight’s severity-specific prevalence estimates for Japan in 2024 reported around 215 thousand, 455 thousand, and 515 thousand cases of mild, moderate, and severe CSU, respectively, with these numbers expected to change in the forecast period (2025–2034).
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.
DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of California, US, Johns Hopkins University School of Medicine, US, Oregon Health and Science University, US, University of Chicago, US, Institute of Allergology, Charité-Universitätsmedizin, Germany, University Hospital of Tours, France, Italian College of General Practitioners and Primary Care, Italy, Association of Chronic Urticaria Affected (AAUC), Spain, St James’s University Hospital, Leeds, UK, Department of Dermatology, Hiroshima Citizens Hospital, Japan, Osaka Medical and Pharmaceutical University, Japan, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Physician’s View
As per the KOLs from the US, a thorough medical history—including potential triggers like infections, medications, and diet—is essential for diagnosing CSU. Assessment tools such as the urticaria activity score, itch severity score, and quality of life measures provide valuable insights into disease burden. Advancing understanding of relevant biomarkers will enhance diagnostic precision and disease characterization.
As per the KOLs from Germany, CSU involves complex immune mechanisms primarily driven by mast cell activation through two main pathways: autoallergic IgE-mediated and autoimmune IgG-mediated processes. This dual-pathway model accounts for the heterogeneous clinical presentation and underscores the need to understand both immune axes to better characterize the disease.
As per the KOLs from Japan, the lack of reliable predictive biomarkers in CSU restricts clinicians’ capacity to accurately assess disease progression, often leading to challenges in timely decision-making. Although markers such as C-reactive protein and D-dimer show correlation with disease activity, their limited predictive accuracy hampers early identification of disease severity, affecting a significant portion of patients. Addressing this gap is essential for improving disease understanding.
Scope of the Report
The report covers a segment of executive summary, descriptive overview of CSU, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.
Chronic Spontaneous Urticaria Report Insights
Patient Population
Country-wise Epidemiology Distribution
Total Diagnosed Prevalent Cases of Chronic Urticaria
Type-specific Cases of Chronic Urticaria
Gender-specific Cases of CSU
Age-specific Cases of CSU
Severity-specific Cases of CSU
Chronic Spontaneous Urticaria Report Key Strengths
10 years Forecast
The 7MM Coverage
CSU Epidemiology Segmentation
Chronic Spontaneous Urticaria Report Assessment
Current Diagnostic Practices Patient Segmentation
Epidemiology Insights
What are the disease risk, burdens, and unmet needs of CSU? What will be the growth opportunities across the 7MM concerning the patient population of CSU?
What is the historical and forecasted CSU patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
Why is the diagnosed prevalent cases of CSU in Japan lower than the US?
Which country has a high patient share for CSU?
Reasons to Buy
Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the CSU prevalent cases in varying geographies over the coming years.
A detailed overview of Gender, Age and Severity-specific diagnosed prevalence of CSU, along with diagnosed prevalent cases of CSU based on symptoms and exacerbation history.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Frequently Asked Questions
1. What is the forecast period covered in the report?
The CSU Epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.
2. Out of all EU4 countries and the UK, which country had the highest population of CSU cases in 2024?
The highest cases of CSU was found in the Germany among EU4 and the UK in 2024.
3. How is epidemiological data collected and analyzed for forecasting purposes?
Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.
4. Out of all 7MM countries, which country had the highest population of CSU cases in 2024?
The highest cases of CSU were found in the Japan among the 7MM in 2024.
DelveInsight’s analyst projects that in 2024, the 7MM reported approximately 4.7 million prevalent cases of chronic urticaria, reflecting a significant disease burden. Of these, approximately 69% were classified as Chronic Spontaneous Urticaria (CSU) and around 31% as chronic inducible urticaria (CIndU), with CSU accounting for the larger proportion.
In 2024, DelveInsight’s analyst estimates that the total number of diagnosed prevalent cases of CSU across the 7MM was approximately 3.2 million. Among these, the US accounted for around 18.5%, EU4 and the UK collectively contributed 44.3%, while Japan accounted for the remaining 37.2%. The diagnosed prevalent cases of CSU across the 7MM are projected to grow at a Compound Annual Growth Rate (CAGR) of approximately 3% over the forecast period (2025–2034).
According to DelveInsight analysis, in 2024, females accounted for approximately 73% of CSU cases in the US, while males represented around 27%. The higher prevalence in females is expected to continue through 2034, primarily due to hormonal and immunological differences that increase susceptibility to autoimmune and allergic conditions such as CSU.
According to DelveInsight’s 2024 estimates, the severity-specific prevalence of CSU in the EU4 and the UK was distributed as approximately 18% mild, 37% moderate, and 45% severe cases. These proportions are expected to increase by 2034 due to evolving diagnostic practices and healthcare technologies.
DelveInsight’s epidemiological model estimates that in 2024, the 18–29 age group in Japan had the highest CSU cases, nearly 300 thousand cases. In contrast, the 60 years and above age group had the fewest cases, with around 60 thousand cases.
CSU is frequently diagnosed through exclusion, which contributes to delayed specialist referrals, excessive diagnostic procedures, and increased patient dissatisfaction—largely driven by limited awareness and recognition of the condition among primary care providers.
DelveInsight’s “Chronic Spontaneous Urticaria (CSU) – Epidemiology Forecast – 2034” report delivers an in-depth understanding of CSU, historical and forecasted epidemiology of CSU in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Geography Covered
The United States
EU4 (Germany, France, Italy, and Spain) and the United Kingdom
Japan
Study Period: 2020–2034
Chronic Spontaneous Urticaria Understanding
CSU Overview
Urticaria is a common and heterogeneous inflammatory skin disorder with or without associated angioedema. It presents with wheals, angioedema, or both due to activation and degranulation of skin mast cells, followed by the release of histamine and other mediators leading to sensory nerve activation, vasodilatation, plasma extravasation, and cellular recruitment. It is classified as acute or chronic, depending on whether the onset of episodes lasts for less or >6 weeks, respectively.
Chronic urticaria is spontaneous or inducible, lasts >6 weeks, and persists for >1 year. It impacts the quality of life and is linked to psychiatric comorbidities and high healthcare costs, often causing huge socio-economic distress for the patients. In contrast to CSU, where the cause is unknown, chronic inducible urticaria has definite and subtype-specific triggers that induce signs and symptoms.
A mast cell-driven disease is characterized by recurrent itchy wheals (hives) that may accompany angioedema, due to activation and degranulation of skin mast cells, followed by the release of histamine and other mediators. The typical lesion is a pale-to-red, well-demarcated papule or plaque. Lesions may be round, oval, annular, arcuate, serpiginous, or generalized. They resolve without post-inflammatory pigmentary changes or scaling. Women are twice as likely as men to be diagnosed with the disease, and most people first develop symptoms between 20 and 40 years.
The etiology of CSU is yet to be fully established. The exact cause is often unknown, but it may be due to autoimmune reactions wherein the immune system mistakenly targets healthy cells in the skin. Other potential triggers include medications, infections, insect bites, stress, and temperature changes. The prognosis in CSU depends on the comorbid disease causing the urticaria and the patient’s response to therapy. The autoimmune pathogenesis of chronic urticaria, including recent data, suggests that CSU may involve contributions from both immunoglobulin G (IgG)-specific and immunoglobulin E (IgE)-specific autoantibodies against a vast array of antigens that can span beyond those found on the surface of mast cells and basophils.
CSU Diagnosis
The diagnosis is based on a physical examination and medical history. Additional tests are performed to rule out underlying causes or to identify triggers, such as blood tests, allergy tests, or skin biopsies. Screening tests for thyroid function and antithyroid peroxidase and antithyroglobulin antibodies are recommended. Positive autologous serum skin test (ASST) and in vitro testing of the patient’s serum for the anti-FCeRIa or the anti-IgE autoantibodies by basophil histamine release assay (BHRA) is also recommended.
Some tools have been developed to assess disease activity (e.g., urticaria activity score), disease control (e.g., urticaria control test), and impacts on quality of life (e.g., chronic urticaria quality of life index).
Further details related to diagnosis are provided in the report…
Chronic Spontaneous Urticaria Epidemiology
For the purpose of designing the patient-based model for CSU, the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of chronic urticaria, type-specific cases of chronic urticaria, gender-specific cases of CSU, age-specific cases of CSU, and severity-specific cases of CSU in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan, from 2020 to 2034.
According to DelveInsight’s estimates, the total diagnosed prevalent cases of chronic urticaria in the 7MM were approximately 4.5 million in 2024, with these numbers anticipated to increase by 2034.
Among the 7MM, the US accounted for nearly 19% of the total diagnosed prevalent cases of chronic urticaria, with around 885 thousand cases in 2024. These cases are expected to change during the forecast period (2025–2034). The EU4 and the UK accounted for approximately 39% of the total cases, while Japan accounted for around 42% in 2024.
DelveInsight’s estimates indicate that type-specific diagnosed prevalent cases of chronic urticaria, including CSU and Chronic Inducible Urticaria (CIndU), were nearly 3.2 million and 1.5 million cases, respectively, in 2024 in the 7MM.
The US accounted for approximately 600 thousand diagnosed prevalent cases of CSU in 2024, and these cases are projected to increase by 2034.
In 2024, among the EU4 and the UK, Germany reported the highest number of diagnosed prevalent cases of CSU with approximately 375 thousand cases, while Spain reported the lowest.
Japan accounted for nearly 37% of the total diagnosed prevalent CSU cases across the 7MM in 2024.
As per the estimates, CSU shows a significant female predominance compared to males. In 2024, the US reported approximately 150 thousand diagnosed prevalent cases of CSU in males and around 430 thousand cases in females, underscoring a significantly higher burden among the female population.
According to DelveInsight’s age-specific prevalence estimates, in the EU4 and the UK, the age group =60 years represented the highest number of diagnosed CSU cases in 2024, with nearly 445 thousand cases, followed by the 50–59 years age group, with around 235 thousand cases.
DelveInsight’s severity-specific prevalence estimates for Japan in 2024 reported around 215 thousand, 455 thousand, and 515 thousand cases of mild, moderate, and severe CSU, respectively, with these numbers expected to change in the forecast period (2025–2034).
KOL Views
To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research on disease prevalence.
DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as the University of California, US, Johns Hopkins University School of Medicine, US, Oregon Health and Science University, US, University of Chicago, US, Institute of Allergology, Charité-Universitätsmedizin, Germany, University Hospital of Tours, France, Italian College of General Practitioners and Primary Care, Italy, Association of Chronic Urticaria Affected (AAUC), Spain, St James’s University Hospital, Leeds, UK, Department of Dermatology, Hiroshima Citizens Hospital, Japan, Osaka Medical and Pharmaceutical University, Japan, and others were contacted. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.
Physician’s View
As per the KOLs from the US, a thorough medical history—including potential triggers like infections, medications, and diet—is essential for diagnosing CSU. Assessment tools such as the urticaria activity score, itch severity score, and quality of life measures provide valuable insights into disease burden. Advancing understanding of relevant biomarkers will enhance diagnostic precision and disease characterization.
As per the KOLs from Germany, CSU involves complex immune mechanisms primarily driven by mast cell activation through two main pathways: autoallergic IgE-mediated and autoimmune IgG-mediated processes. This dual-pathway model accounts for the heterogeneous clinical presentation and underscores the need to understand both immune axes to better characterize the disease.
As per the KOLs from Japan, the lack of reliable predictive biomarkers in CSU restricts clinicians’ capacity to accurately assess disease progression, often leading to challenges in timely decision-making. Although markers such as C-reactive protein and D-dimer show correlation with disease activity, their limited predictive accuracy hampers early identification of disease severity, affecting a significant portion of patients. Addressing this gap is essential for improving disease understanding.
Scope of the Report
The report covers a segment of executive summary, descriptive overview of CSU, explaining its causes, signs and symptoms, and currently available diagnostic algorithms and guidelines.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and diagnosis guidelines.
The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
A detailed review of current challenges in establishing the diagnosis.
Chronic Spontaneous Urticaria Report Insights
Patient Population
Country-wise Epidemiology Distribution
Total Diagnosed Prevalent Cases of Chronic Urticaria
Type-specific Cases of Chronic Urticaria
Gender-specific Cases of CSU
Age-specific Cases of CSU
Severity-specific Cases of CSU
Chronic Spontaneous Urticaria Report Key Strengths
10 years Forecast
The 7MM Coverage
CSU Epidemiology Segmentation
Chronic Spontaneous Urticaria Report Assessment
Current Diagnostic Practices Patient Segmentation
Epidemiology Insights
What are the disease risk, burdens, and unmet needs of CSU? What will be the growth opportunities across the 7MM concerning the patient population of CSU?
What is the historical and forecasted CSU patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
Why is the diagnosed prevalent cases of CSU in Japan lower than the US?
Which country has a high patient share for CSU?
Reasons to Buy
Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand the CSU prevalent cases in varying geographies over the coming years.
A detailed overview of Gender, Age and Severity-specific diagnosed prevalence of CSU, along with diagnosed prevalent cases of CSU based on symptoms and exacerbation history.
To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis options.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Frequently Asked Questions
1. What is the forecast period covered in the report?
The CSU Epidemiology report for the 7MM covers the forecast period from 2025 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.
2. Out of all EU4 countries and the UK, which country had the highest population of CSU cases in 2024?
The highest cases of CSU was found in the Germany among EU4 and the UK in 2024.
3. How is epidemiological data collected and analyzed for forecasting purposes?
Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.
4. Out of all 7MM countries, which country had the highest population of CSU cases in 2024?
The highest cases of CSU were found in the Japan among the 7MM in 2024.
Table of Contents
100 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. CSU Epidemiology Overview at a Glance
- 3.1. Patient Share (%) Distribution of CSU in 2024
- 3.2. Patient Share (%) Distribution of CSU in 2034
- 4. Executive Summary
- 5. Disease Background and Overview
- 5.1. Introduction
- 5.2. Signs and symptoms
- 5.3. Classification
- 5.3.1. Classification of Urticaria Based on Its Duration and the Relevance of Eliciting Factors
- 5.4. Causes
- 5.5. Pathophysiology
- 5.6. Clinical Manifestation
- 5.7. Diagnosis
- 5.7.1. Diagnostic Algorithm
- 5.7.2. Diagnostic Guidelines and Recommendations
- 6. Methodology
- 7. Epidemiology and Patient Population
- 7.1. Key Findings
- 7.2. Assumptions and Rationale: The 7MM
- 7.2.1. Diagnosed Prevalent Cases of Chronic Urticaria
- 7.2.2. Type-specific Cases of Chronic Urticaria
- 7.2.3. Gender-specific Cases of CSU
- 7.2.4. Age-specific Cases of CSU
- 7.2.5. Severity-specific Cases of CSU
- 7.3. Total Diagnosed Prevalent Cases of CSU in the 7MM
- 7.4. The US
- 7.4.1. Total Diagnosed Prevalent Cases of Chronic Urticaria in the US
- 7.4.2. Type-specific Cases of Chronic Urticaria in the US
- 7.4.3. Gender-specific Cases of CSU in the US
- 7.4.4. Age-specific Cases of CSU in the US
- 7.4.5. Severity-specific Cases of CSU in the US
- 7.5. EU4 and the UK
- 7.5.1. Total Diagnosed Prevalent Cases of Chronic Urticaria in EU4 and the UK
- 7.5.2. Type-specific Cases of Chronic Urticaria in EU4 and the UK
- 7.5.3. Gender-specific Cases of CSU in EU4 and the UK
- 7.5.4. Age-specific Cases of CSU in EU4 and the UK
- 7.5.5. Severity-specific Cases of CSU in EU4 and the UK
- 7.6. Japan
- 7.6.1. Total Diagnosed Prevalent Cases of Chronic Urticaria in Japan
- 7.6.2. Type-specific Cases of Chronic Urticaria in Japan
- 7.6.3. Gender-specific Cases of CSU in Japan
- 7.6.4. Age-specific Cases of CSU in Japan
- 7.6.5. Severity-specific Cases of CSU in Japan
- 8. Patient Journey
- 9. Key Opinion Leaders’ Views
- 10. Appendix
- 10.1. Acronyms and Abbreviations
- 10.2. Bibliography
- 10.3. Report Methodology
- 11. DelveInsight Capabilities
- 12. Disclaimer
- 13. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
